학술논문
The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-Arm, open-label, phase 3 trial
Document Type
Article
Author
Source
In: Saudi Journal of Gastroenterology . (Saudi Journal of Gastroenterology, May-June 2022, 28(3):225-232)
Subject
Language
English
ISSN
19984049
13193767
13193767